Navigation Links
Delay in Start of VNUS Patent Litigation and Court Ruling on Summary Judgment Motion
Date:10/22/2007

SAN JOSE, Calif., Oct. 22 /PRNewswire-FirstCall/ -- The start of the patent lawsuit by VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS) against three endovenous laser competitors, Diomed, AngioDynamics and Vascular Solutions, has been delayed from a previously scheduled start date of October 29. The delay is due to a busy court calendar. A court conference is scheduled for October 26 to identify potential new trial start dates. At the conference, the parties will seek to have the trial start during the first quarter of 2008.

In addition, the judge today issued a ruling denying defendants' summary judgment motion that asked to declare two of VNUS' patents invalid. Accordingly, the case will proceed to trial on all three of the patents that VNUS seeks to enforce.

ABOUT VNUS MEDICAL TECHNOLOGIES, INC.

VNUS Medical Technologies (Nasdaq: VNUS) is a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition that causes the varicose veins afflicting 25 million Americans. The pioneering company in the field, VNUS now offers the ClosureFAST(R) system, which consists of a proprietary radiofrequency (RF) generator and proprietary disposable endovenous catheters and devices to close diseased veins through the application of temperature-controlled RF energy. For more information, please visit http://www.vnus.com.

FORWARD-LOOKING STATEMENTS

In addition to statements of historical facts or statements of current conditions, VNUS has made forward-looking statements in this press release regarding patent litigation. The reader is cautioned not to unduly rely on these forward-looking statements. VNUS expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.


'/>"/>
SOURCE VNUS Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Depression may cause delayed wound healing
2. The Effects Of Delaying A Delivery Questioned
3. UK Facing Shortage of Radiotherapists Delaying Cancer Treatment
4. Smoking Delays Pregnancy
5. Influenza drug delayed
6. Glaucoma may be delayed by eye drops
7. Calcium-blocker delays atherosclerosis than beta-blockers
8. Running delays disability in the aged
9. Delaying Parkinson’s Diseas
10. Lifestyle changes Can Delay the Onset Of Dementia
11. Lifestyle changes Can Delay the Onset Of Dementia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 29, 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown ... of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , ... 70% tax credit to individuals and corporations which donate directly to a “rural hospital” ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for ... Island Park on Sunday, with sunny skies, a light breeze and temperatures in the ... , The 5k Run and Walk and 1-mile walk were held to ...
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip ... meal to miss. That was among the many new lifestyle diet tips offered by ... Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that because ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016 ... H1 2016" market research report that provides an ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s announced ... the company,s valve repair and stent business, healthcare ... places Abbott more firmly into patient monitoring.  Kalorama ... fastest growing device areas, with double-digit growth expected ... report,  Advanced Remote Patient Monitoring . ...
Breaking Medicine Technology: